» Articles » PMID: 31451034

Systemic Therapy for the Treatment of Endometrial Cancer

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2019 Aug 28
PMID 31451034
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

: Endometrial cancer (EC) is one of the most frequent gynecological cancers worldwide. The gold standard treatment of EC is most certainly surgery and may very well be the only therapy in the early stages of disease. To improve outcomes in non-early EC, adjuvant therapy is often employed but this is not standardized. Adjuvant options can include radiotherapy, chemotherapy or a combination of both. Adjuvant chemotherapy could be indicated in high-risk stage I and II or advanced stage EC. Several clinical trials are ongoing in an attempt to define the optimal adjuvant treatment. Furthermore, chemotherapy is the front-line therapy in advanced unresectable, metastatic or recurrent endometrial cancer. : Herein, the authors review the first-line chemotherapy for the treatment of endometrial cancer and provide their expert perspectives on these therapies. : Chemotherapy is fundamental in advanced/recurrent EC. Further evidence is needed to characterize the role of adjuvant chemotherapy. Future studies should consider genomic and molecular heterogeneities to identify even more efficient tailored therapies.

Citing Articles

CPA4 overexpression correlates with poor prognosis and tumor progression in endometrial cancer.

He K, Zheng J, Zhang T, Lv H, Wang K, Wang Z Eur J Med Res. 2025; 30(1):174.

PMID: 40089797 DOI: 10.1186/s40001-025-02293-0.


Dedifferentiated endometrial carcinoma metastasis to axillary lymph node: a case report.

Morrison C, Sanjasaz K, Nathanson S, Raina-Hukku S, Pinkney D, Davenport A J Med Case Rep. 2023; 17(1):451.

PMID: 37899461 PMC: 10614416. DOI: 10.1186/s13256-023-04192-6.


Endometrial Adenocarcinoma in Young Women: A Case Report and Review of Literature.

Satei J, Afrakhteh A, Aldecoa K Cureus. 2023; 15(9):e45287.

PMID: 37846282 PMC: 10576867. DOI: 10.7759/cureus.45287.


Reducing the Invasiveness of Low- and High-Grade Endometrial Cancers in Both Primary Human Cancer Biopsies and Cell Lines by the Inhibition of Aquaporin-1 Channels.

Khan S, Lokman N, Oehler M, Ricciardelli C, Yool A Cancers (Basel). 2023; 15(18).

PMID: 37760476 PMC: 10526386. DOI: 10.3390/cancers15184507.


KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.

He K, Li J, Huang X, Zhao W, Wang K, Wang T Front Oncol. 2023; 13:1090779.

PMID: 36776306 PMC: 9913269. DOI: 10.3389/fonc.2023.1090779.